Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
04:45pm, Monday, 12'th May 2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
08:30am, Monday, 05'th May 2025
COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone d
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
09:35pm, Thursday, 01'st May 2025
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and
Ascendis Pharma Reports First Quarter 2025 Financial Results
04:01pm, Thursday, 01'st May 2025
- Q1 2025 revenue of €44.7 million for YORVIPATH ® and €51.3 million for SKYTROFA ® - TransCon ™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination tri
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
04:01pm, Thursday, 24'th Apr 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
10:46am, Wednesday, 16'th Apr 2025
Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
04:38pm, Monday, 14'th Apr 2025
Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launc
Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting
06:30am, Monday, 14'th Apr 2025
TORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and f
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
04:01pm, Monday, 31'st Mar 2025
— Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondrop
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
10:50am, Tuesday, 18'th Mar 2025
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
04:01pm, Monday, 24'th Feb 2025
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
02:40pm, Thursday, 13'th Feb 2025
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
11:03pm, Wednesday, 12'th Feb 2025
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Ch
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
04:05pm, Wednesday, 12'th Feb 2025
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Wednesday, 12'th Feb 2025
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
